Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Cardiomyopathy II: Dilated Cardiomyopathy

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...

Cardiomyopathy V: Interprofessional Care

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...

Heart Failure Drugs: Inotropic Agents

Heart Failure Drugs: Inotropic Agents

Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...

Cardiomyopathy VI: Nursing Management

Cardiomyopathy VI: Nursing Management

Assessment: Nursing management of patients with cardiomyopathy begins with a thorough assessment of the patient's history, including a family history of cardiomyopathy or sudden cardiac death, personal history of heart disease, hypertension, diabetes, and any alcohol consumption or drug use.During the physical examination, assess vital signs, look for signs of heart failure (such as edema, jugular venous distention, and cyanosis), auscultate for abnormal heart sounds (like murmurs and gallops),...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Arrhythmias in Patients with Cancer: Pathophysiology, Risk Stratification and Clinical Implications.

Trends in cardiovascular medicine·2026

Same author

Pan-cancer multi-omic integration of Trop2 reveals biological determinants and translational implications for ADC therapy.

NPJ precision oncology·2026

Same author

The promyelocytic leukemia PML protein coordinates immune evasion in triple-negative breast cancer via independent and converging mechanisms.

Cell death and differentiation·2026

Same author

Pharmacological strategies to prevent cancer therapy-related cardiovascular toxicity: the road to personalised cardioprotection.

Heart (British Cardiac Society)·2026

Same author

Cardiovascular signaling proteins as predictors of the cardiac effects of doxorubicin treatment in children with acute lymphoblastic leukemia.

Cardio-oncology (London, England)·2026

Same author

Effect of prophylactic antibiotics on days of antibiotic spectrum coverage in comatose post-cardiac arrest patients: a secondary analysis of PROTECT.

JAC-antimicrobial resistance·2026

Search research articles

Related Experiment Video

Updated: Jul 3, 2026

A Doxorubicin-Induced Murine Model of Dilated Cardiomyopathy In Vivo

A Doxorubicin-Induced Murine Model of Dilated Cardiomyopathy In Vivo

Published on: May 16, 2020

Anthracycline cardiotoxicity: from bench to bedside.

Luca Gianni¹, Eugene H Herman, Steven E Lipshultz

¹Division of Medical Oncology, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico, Instituto Nazionale Tumori, Milan, Italy.

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology

|August 2, 2008

Summary

Anthracyclines are vital anticancer drugs, but their use is limited by severe heart damage (cardiotoxicity). Further research is crucial to understand and mitigate this dangerous side effect.

More Related Videos

A Doxorubicin-induced Cardiomyopathy Model in Adult Zebrafish

A Doxorubicin-induced Cardiomyopathy Model in Adult Zebrafish

Published on: June 7, 2018

Chemotherapy-induced Vascular Toxicity - Real-time In vivo Imaging of Vessel Impairment

Chemotherapy-induced Vascular Toxicity - Real-time In vivo Imaging of Vessel Impairment

Published on: January 7, 2015

Related Experiment Videos

Last Updated: Jul 3, 2026

A Doxorubicin-Induced Murine Model of Dilated Cardiomyopathy In Vivo

A Doxorubicin-Induced Murine Model of Dilated Cardiomyopathy In Vivo

Published on: May 16, 2020

A Doxorubicin-induced Cardiomyopathy Model in Adult Zebrafish

A Doxorubicin-induced Cardiomyopathy Model in Adult Zebrafish

Published on: June 7, 2018

Chemotherapy-induced Vascular Toxicity - Real-time In vivo Imaging of Vessel Impairment

Chemotherapy-induced Vascular Toxicity - Real-time In vivo Imaging of Vessel Impairment

Published on: January 7, 2015

Area of Science:

Oncology
Cardiology
Pharmacology

Background:

Anthracyclines are essential chemotherapy agents with significant anticancer efficacy.
Cardiotoxicity remains a major dose-limiting toxicity, compromising clinical utility.
Pathogenic mechanisms of anthracycline cardiotoxicity are not fully understood despite extensive research.

Framework:

The First International Workshop on Anthracycline Cardiotoxicity convened experts to discuss current knowledge.
Focus was placed on the state-of-the-art understanding of anthracycline-induced heart damage.
Discussions aimed to identify critical research gaps and future directions.

Implementation:

This review integrates workshop discussions into a comprehensive overview.
Preclinical findings related to anthracycline cardiotoxicity are examined.
Clinical aspects and patient management strategies are also addressed.

Implications:

Elucidating cardiotoxicity mechanisms is vital for safer cancer treatment.
New therapeutic strategies may be developed to prevent or treat heart damage.
Improved understanding will aid in managing combination therapies involving anthracyclines.